From: Practice effects in a longitudinal, multi-center Alzheimer’s disease prevention clinical trial
All participants with alternating versions (n = 1,803) | ||||
---|---|---|---|---|
Baseline MIS | FU 1 MIS | FU 2 MIS | FU 3 MIS | |
MIS score, mean (SD) | 7.34 (0.74) | 7.47 (0.68) | 7.48 (0.70) | 7.54 (0.69) |
MIS score, n (%) | ||||
≤ 5 | 45 (2.5%) | 24 (1.3%) | 30 (1.7%) | 33 (1.8%) |
6 | 151 (8.4%) | 123 (6.8%) | 128 (7.1%) | 103 (5.7%) |
7 | 759 (42.1%) | 632 (35.1%) | 596 (33.1%) | 527 (29.2%) |
8 | 848 (47.0%) | 1,024 (56.8%) | 1,049 (58.2%) | 1,140 (63.2%) |
Total | 1,803 (100%) | 1,803 (100%) | 1,803 (100%) | 1,803 (100%) |
Participants age 75 years or more at baseline with alternating versions (n = 218) | ||||
Baseline MIS | FU 1 MIS | FU 2 MIS | FU 3 MIS | |
MIS score, mean (SD) | 7.30 (0.81) | 7.41 (0.71) | 7.33 (0.76) | 7.32 (0.82) |
MIS score, n (%) | ||||
≤ 5 | 8 (3.7%) | 2 (0.9%) | 5 (2.3%) | 10 (4.6%) |
6 | 24 (11.0%) | 22 (10.1%) | 23 (10.6%) | 19 (8.7%) |
7 | 80 (36.7%) | 79 (36.2%) | 84 (38.5%) | 80 (36.7%) |
8 | 106 (48.6%) | 115 (52.8%) | 106 (48.6%) | 109 (50.0%) |
Total | 218 (100%) | 218 (100%) | 218 (100%) | 218 (100%) |